What Is MGUS?
MGUS is a condition marked by the presence of an abnormal antibody in the blood. This antibody, known as a monoclonal protein, or M protein, is produced by plasma cells, or B lymphocytes, typically in the bone marrow. MGUS is present in roughly 3%-5% of the population above age 50.
MGUS can lead to more severe conditions, with the most common being multiple myeloma, a blood cancer of the plasma cells. MGUS can also lead to lymphomas such as Waldenstrom macroglobulinemia, AL amyloidosis, and monoclonal gammopathies of clinical significance (MGCS).
Because of this risk of progression, MGUS is called a precursor condition. It is generally considered precancerous, though MGUS itself is benign. And while it’s important to monitor MGUS, it usually doesn’t progress into a more serious disease. Most patients will not develop multiple myeloma or another blood cancer.
UT Southwestern’s Monoclonal Gammopathy Precursor (MGP) team helps patients receive accurate diagnoses and personalized monitoring based on the latest medical guidelines. Our goal is to detect any changes early, provide peace of mind, and offer proactive care that aligns with each patient's needs.
Our team includes renowned specialists trained by prominent leaders in myeloma and monoclonal gammopathy research. This depth of expertise allows us to provide leading-edge treatment and management strategies.